Email this Page
Print this Page 
CALGB 50303 - Phase III Randomized Study of R-Chop V. Dose-Adjusted Epoch-R (DA-EPOCH-R) with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
CALGB 50604 - Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
CALGB 50801 - Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
CALGB 50904 - Phase II Trial Ofatumumab & Bendamustine with & without Bortezomib in Untreated Foll. Lymphoma
GCC 0851 - Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response. BMT/CTN 0701
GCC 0922 - Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-cell Lymphomas. NCI Protocol 8064
GCC 0942 - A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics [PK]-directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non- Hodgkins Lymphoma and Hodgkins Lymphoma
GCC 1027 - Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
GCC 1135 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
GCC 1168 - A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL
GCC 1226 - A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy
|
Email this Page
Print this Page
|
